5,011 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Article Searches
Why Investors Should Retain Restaurant Brands (QSR) Stock Now https://www.zacks.com/stock/news/2196862/why-investors-should-retain-restaurant-brands-qsr-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2196862 Dec 12, 2023 - Restaurant Brands (QSR) benefits from strong comparable sales, ongoing expansion initiatives, menu innovations and robust digital sales.
Bears are Losing Control Over Lifeway (LWAY), Here's Why It's a 'Buy' Now https://www.zacks.com/stock/news/2196818/bears-are-losing-control-over-lifeway-lway-here-s-why-it-s-a-buy-now?cid=CS-ZC-FT-tale_of_the_tape|hammer_chart_pattern_(ta)-2196818 Dec 12, 2023 - Lifeway (LWAY) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Is RPM International (RPM) Stock Undervalued Right Now? https://www.zacks.com/stock/news/2196776/is-rpm-international-rpm-stock-undervalued-right-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_2-2196776 Dec 12, 2023 - Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is Rio Tinto (RIO) a Great Value Stock Right Now? https://www.zacks.com/stock/news/2196777/is-rio-tinto-rio-a-great-value-stock-right-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_2-2196777 Dec 12, 2023 - Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is New Gold (NGD) Stock Undervalued Right Now? https://www.zacks.com/stock/news/2196778/is-new-gold-ngd-stock-undervalued-right-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_2-2196778 Dec 12, 2023 - Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
2 Underrated Warren Buffett Stocks That Are Smart Buys Right Now https://www.fool.com/investing/2023/12/12/2-underrated-warren-buffett-stocks-that-are-smart/?source=iedfolrf0000001 Dec 12, 2023 - Amazon and Visa are small parts of Berkshire's portfolio, but they look attractive right now.
Here's Why Investors Should Retain ResMed (RMD) Stock for Now https://www.zacks.com/stock/news/2196711/here-s-why-investors-should-retain-resmed-rmd-stock-for-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2196711 Dec 12, 2023 - Investors continue to be optimistic about ResMed (RMD) due to the sustained growth in the SaaS business.
Why Investors Need to Take Advantage of These 2 Consumer Staples Stocks Now https://www.zacks.com/stock/news/2196660/why-investors-need-to-take-advantage-of-these-2-consumer-staples-stocks-now?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_earnings_esp-2196660 Dec 12, 2023 - Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
If You Invested $1000 in American Tower 10 Years Ago, This Is How Much You'd Have Now https://www.zacks.com/stock/news/2196636/if-you-invested-1000-in-american-tower-10-years-ago-this-is-how-much-you-d-have-now?cid=CS-ZC-FT-tale_of_the_tape|investing_$1000-2196636 Dec 12, 2023 - Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
Reasons to Add Cardinal Health (CAH) to Your Portfolio Now https://www.zacks.com/stock/news/2196582/reasons-to-add-cardinal-health-cah-to-your-portfolio-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2196582 Dec 12, 2023 - Cardinal Health (CAH) continues to gain traction from a solid pharmaceutical segment and a diversified product portfolio. However, the rising cost of products is a concern.
<<<Page 479>